scholarly journals Is placebo useful in the treatment of major depression in clinical practice?

2013 ◽  
pp. 915 ◽  
Author(s):  
Carlo Marchesi ◽  
De Panfilis ◽  
Tonna ◽  
Paolo Ossola
Keyword(s):  
Clinical Practice ◽  
Major Depression

The Rise of Aggressive Psychopharmacology

2020 ◽  
pp. 139-148
Author(s):  
Joel Paris
Keyword(s):  
Clinical Practice ◽  
Major Depression ◽  
Pharmaceutical Industry ◽  
Mental Disorders ◽  
Mental Disorder ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Evidence Base ◽  
Weak Evidence ◽  
Wide Range

Aggressive psychopharmacology describes the current practice of prescribing a large number of medications to patients with almost any mental disorder. While there is some evidence for this approach in severe and, persistent mental disorders, it has spread to common disorders, most particularly major depression. Clinical practice guidelines, which offer a wide range options for patients who are resistant to standard treatments, are being interpreted as promoting polypharmacy for a very broad group of patient. These practices have a surprisingly weak evidence base, and tend to take psychotherapy options off the table. Aggressive psychoharmacology is driven by overdiagnosis and is strongly encouraged by the pharmaceutical industry.

Effectiveness and Safety of Vagus Nerve Stimulation for Severe Treatment-Resistant Major Depression in Clinical Practice After FDA Approval

2011 ◽  
Vol 72 (10) ◽  
pp. 1376-1382 ◽  
Author(s):  
Pilar Cristancho ◽  
Mario A. Cristancho ◽  
Gordon H. Baltuch ◽  
Michael E. Thase ◽  
John P. O’Reardon
Keyword(s):  
Clinical Practice ◽  
Major Depression ◽  
Vagus Nerve ◽  
Nerve Stimulation ◽  
Vagus Nerve Stimulation ◽  
Treatment Resistant ◽  
Fda Approval

Remission, Residual Symptoms, and Nonresponse in the Usual Treatment of Major Depression in Managed Clinical Practice

2003 ◽  
Vol 64 (4) ◽  
pp. 397-402 ◽  
Author(s):  
Brian J. Cuffel ◽  
Francisca Azocar ◽  
Molly Tomlin ◽  
Shelly F. Greenfield ◽  
Alisa B. Busch ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Major Depression ◽  
Residual Symptoms ◽  
Usual Treatment

scholarly journals Relationship of Premenstrual Syndrome and Premenstrual Dysphoric Disorder with Major Depression: Relevance to Clinical Practice

2015 ◽  
Vol 37 (2) ◽  
pp. 159-164 ◽  
Author(s):  
Susanta Kumar Padhy ◽  
Sidharth Sarkar ◽  
Prakash B. Beherre ◽  
Rajesh Rathi ◽  
Mahima Panigrahi ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Major Depression ◽  
Premenstrual Syndrome ◽  
Premenstrual Dysphoric Disorder ◽  
Relationship Of

Are Antidepressants All the Same? Surveying the Opinions of Australian Psychiatrists

1999 ◽  
Vol 33 (5) ◽  
pp. 642-649 ◽  
Author(s):  
Ian B. Hickie ◽  
Elizabeth M. Scott ◽  
Tracey A. Davenport
Keyword(s):  
Clinical Practice ◽  
Major Depression ◽  
Monoamine Oxidase ◽  
Serotonin Receptor ◽  
Monoamine Oxidase Inhibitor ◽  
Oxidase Inhibitor ◽  
Receptor Subtype ◽  
Reversible Inhibitors ◽  
Uptake Inhibitors ◽  
Wide Range

Objective: Controlled trials do not suggest differences in efficacy between antidepressant compounds. Psychiatrists, however, frequently express the view that real differences do exist and are relevant to clinical practice. Since multiple comparative trials are not feasible, an alternative method for expanding the evidence base is to survey regularly the opinions of practising psychiatrists. Method: Two surveys of psychiatrists' opinions were conducted. Participants in the first survey were drawn from contact with ‘SPHERE: A National Depression Project’, while those in the second survey responded to a brief questionnaire distributed with Australasian Psychiatry. Results: Reported volumes of scripts written, ratings of efficacy and tolerability, and preferences in specific clinical situations indicate that clinical psychiatrists now strongly prefer the newer antidepressant agents. They rate serotonin and noradren-alin re-uptake inhibitors (SNRIs) and selective serotonin re-uptake inhibitors (SSRIs) highest for antidepressant efficacy, serotonin receptor subtype 2 (5HT2) antagonists and some SSRIs highest for anti-anxiety efficacy, and some SSRIs and reversible inhibitors of monoamine oxidase inhibitor-A (RIMAs) lowest for side-effect burden. Further, SSRIs were their first preferences for most clinical situations. Serotonin and noradrenalin re-uptake inhibitors were the preferred choice for treatment-resistant depression and patients who had failed to respond to one SSRI. Serotonin receptor subtype 2 antagonists were the second choice to SSRIs for mixed anxiety and depression, and major depression with sleep disturbance. Reversible inhibitors of monoamine oxidase inhibitor-A were the second choice to SSRIs for adolescents with major depression, patients aged over 65 years, patients with serious medical illnesses and patients with chronic fatigue. Tricyclic antidepressants (TCAs) were the preferred choice for patients with chronic pain, and second choice to SSRIs for patients with major depression with panic disorder, postnatal disorders and patients with psychotic depression. Conclusion: Psychiatrists believe that important differences do exist between available antidepressant compounds. Such opinions are divergent from limited controlled data but may be influenced by a wide range of factors other than direct clinical experience. The role of such surveys in ongoing evaluation of clinical practice is emphasised.

scholarly journals Alexithymia, Suicide Ideation and Homocysteine Levels in Drug Naïve Patients with Major Depression: A Study in the “Real World” Clinical Practice

2019 ◽  
Vol 17 (2) ◽  
pp. 318-322 ◽  
Author(s):  
Domenico De Berardis ◽  
Luigi Olivieri ◽  
Gabriella Rapini ◽  
Serena Di Natale ◽  
Nicola Serroni ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Major Depression ◽  
Real World ◽  
Suicide Ideation ◽  
The Real ◽  
Drug Naïve
Sign in / Sign up

Export Citation Format

Share Document